{"id":5613,"date":"2023-11-15T11:34:41","date_gmt":"2023-11-15T16:34:41","guid":{"rendered":"https:\/\/neoaptamers.com\/?p=5613"},"modified":"2026-04-13T14:24:46","modified_gmt":"2026-04-13T18:24:46","slug":"aptamers-a-novel-therapeutic-oligonucleotide","status":"publish","type":"post","link":"https:\/\/neoaptamers.com\/es\/aptamers-a-novel-therapeutic-oligonucleotide\/","title":{"rendered":"Apt\u00e1meros: Un Oligonucle\u00f3tido Terap\u00e9utico Innovador"},"content":{"rendered":"

En el campo de la medicina molecular, que avanza r\u00e1pidamente, los investigadores est\u00e1n constantemente en busca de terapias innovadoras que puedan dirigirse con precisi\u00f3n y eficacia a mol\u00e9culas espec\u00edficas de enfermedades. Los apt\u00e1meros, una clase de oligonucle\u00f3tidos sint\u00e9ticos, han surgido como una herramienta prometedora y vers\u00e1til en la b\u00fasqueda de terapias m\u00e1s efectivas. En este blog, exploraremos el fascinante mundo de los apt\u00e1meros, sus propiedades \u00fanicas y su potencial para revolucionar el tratamiento de diversas condiciones m\u00e9dicas.<\/p>\n

\u00bfQu\u00e9 son los Apt\u00e1meros?<\/h3>\n

Los apt\u00e1meros son mol\u00e9culas cortas de ADN o ARN de una sola cadena que pueden unirse selectivamente a mol\u00e9culas espec\u00edficas, como prote\u00ednas, \u00e1cidos nucleicos o incluso mol\u00e9culas peque\u00f1as. Estas mol\u00e9culas a menudo se denominan \"anticuerpos qu\u00edmicos\" debido a su capacidad para reconocer y unirse a sus objetivos con alta afinidad y especificidad.<\/p>\n

El Proceso de Selecci\u00f3n<\/h3>\n

El proceso de creaci\u00f3n de apt\u00e1meros implica una t\u00e9cnica llamada evoluci\u00f3n sistem\u00e1tica de ligandos por enriquecimiento exponencial (SELEX, por sus siglas en ingl\u00e9s). Durante SELEX, una biblioteca aleatoria de secuencias de ADN o ARN se expone a la mol\u00e9cula objetivo. Las secuencias que se unen al objetivo se a\u00edslan y amplifican a trav\u00e9s de m\u00faltiples rondas de selecci\u00f3n. Este proceso iterativo resulta en la identificaci\u00f3n de apt\u00e1meros con la mayor afinidad de uni\u00f3n para el objetivo.<\/p>\n

Ventajas de los Apt\u00e1meros<\/h3>\n
    \n
  1. Alta Especificidad: Los apt\u00e1meros muestran una especificidad excepcional para sus mol\u00e9culas objetivo, minimizando los efectos fuera del objetivo.<\/li>\n
  2. Versatilidad: Pueden ser dise\u00f1ados para unirse a una amplia gama de objetivos, incluyendo prote\u00ednas, toxinas e incluso c\u00e9lulas cancerosas.<\/li>\n
  3. Estabilidad: Los apt\u00e1meros son estables y pueden resistir diversas condiciones ambientales, lo que los hace adecuados para diferentes aplicaciones.<\/li>\n
  4. Baja Inmunogenicidad: A diferencia de otros agentes terap\u00e9uticos, los apt\u00e1meros tienen baja inmunogenicidad, lo que reduce el riesgo de respuestas inmunes adversas.<\/li>\n<\/ol>\n

    Aplicaciones de los Apt\u00e1meros<\/h3>\n
      \n
    1. Diagn\u00f3sticos: Los apt\u00e1meros se utilizan en pruebas diagn\u00f3sticas para detectar biomarcadores espec\u00edficos asociados con enfermedades, lo que permite el diagn\u00f3stico temprano de enfermedades y su monitoreo.<\/li>\n
    2. Entrega de F\u00e1rmacos: Los apt\u00e1meros pueden ser conjugados con f\u00e1rmacos, nanopart\u00edculas o liposomas, facilitando la entrega dirigida de f\u00e1rmacos a sitios de enfermedad y reduciendo los efectos secundarios.<\/li>\n
    3. Terap\u00e9utica: Los apt\u00e1meros han mostrado ser prometedores como terapias para diversas condiciones, incluyendo el c\u00e1ncer, enfermedades autoinmunes e infecciones virales. Pueden bloquear la actividad de prote\u00ednas relacionadas con la enfermedad o entregar cargas terap\u00e9uticas a c\u00e9lulas espec\u00edficas.<\/li>\n
    4. Biosensores: Los apt\u00e1meros son componentes integrales de los biosensores, proporcionando monitoreo en tiempo real de eventos moleculares en muestras biol\u00f3gicas.<\/li>\n<\/ol>\n

      Ejemplos de Terapias Basadas en Apt\u00e1meros<\/h3>\n
        \n
      1. Pegaptanib (Macugen): Aprobado por la FDA, el pegaptanib es una terapia basada en apt\u00e1meros utilizada para tratar la degeneraci\u00f3n macular relacionada con la edad al inhibir el factor de crecimiento endotelial vascular (VEGF).<\/li>\n
      2. NOX-A12: Este apt\u00e1mero se dirige al receptor de quimiocina CXCL12 y est\u00e1 siendo investigado como un posible tratamiento para el mieloma m\u00faltiple y la leucemia linfoc\u00edtica cr\u00f3nica.<\/li>\n
      3. AS1411: AS1411 es un apt\u00e1mero que se une a la nucleolina, una prote\u00edna sobreexpresada en c\u00e9lulas cancerosas. Se est\u00e1 estudiando por sus propiedades anticancer\u00edgenas.<\/li>\n<\/ol>\n

        Desaf\u00edos y Futuras Direcciones<\/h3>\n

        Si bien los apt\u00e1meros tienen un gran potencial, existen varios desaf\u00edos que deben abordarse. Estos incluyen mejorar su estabilidad, aumentar su entrega a tejidos espec\u00edficos y reducir los costos de producci\u00f3n. Los investigadores est\u00e1n trabajando activamente para superar estos obst\u00e1culos y ampliar las aplicaciones cl\u00ednicas de los apt\u00e1meros.<\/p>\n

        Los apt\u00e1meros representan una nueva clase de oligonucle\u00f3tidos terap\u00e9uticos con un tremendo potencial para revolucionar el campo de la medicina. Su alta especificidad, versatilidad y estabilidad los convierten en herramientas valiosas para diagn\u00f3sticos, entrega de f\u00e1rmacos y terapias dirigidas. A medida que la investigaci\u00f3n en este campo contin\u00faa avanzando, podemos esperar un futuro en el que los apt\u00e1meros jueguen un papel central en el tratamiento de una amplia gama de enfermedades, mejorando los resultados para los pacientes y allanando el camino para una medicina m\u00e1s personalizada y efectiva.<\/p>","protected":false},"excerpt":{"rendered":"

        In the rapidly advancing field of molecular medicine, researchers are constantly on the lookout for innovative therapies that can target specific disease molecules with precision and efficacy. Aptamers, a class of synthetic oligonucleotides, have emerged as a promising and versatile tool in the quest for more effective therapeutics. In this blog, we will explore the… Leer m\u00e1s »Apt\u00e1meros: Un Oligonucle\u00f3tido Terap\u00e9utico Innovador<\/span><\/a><\/p>","protected":false},"author":2,"featured_media":5615,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-5613","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aptamers"],"yoast_head":"\nAptamers: A Novel Therapeutic Oligonucleotide<\/title>\n<meta name=\"description\" content=\"Explore the potential of aptamers as a novel therapeutic in medicine with high specificity and versatility for disease treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/es\/aptamers-a-novel-therapeutic-oligonucleotide\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptamers: A Novel Therapeutic Oligonucleotide\" \/>\n<meta property=\"og:description\" content=\"Explore the potential of aptamers as a novel therapeutic in medicine with high specificity and versatility for disease treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/es\/aptamers-a-novel-therapeutic-oligonucleotide\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-15T16:34:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T18:24:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._a_bioscientist_in_a_lab_filled_with_light_studying_apta_3aac6d2e-4067-4208-8ce6-aed99945d942.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1456\" \/>\n\t<meta property=\"og:image:height\" content=\"816\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Gregory Penner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gregory Penner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/\"},\"author\":{\"name\":\"Gregory Penner\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\"},\"headline\":\"Aptamers: A Novel Therapeutic Oligonucleotide\",\"datePublished\":\"2023-11-15T16:34:41+00:00\",\"dateModified\":\"2026-04-13T18:24:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/\"},\"wordCount\":555,\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._a_bioscientist_in_a_lab_filled_with_light_studying_apta_3aac6d2e-4067-4208-8ce6-aed99945d942.png\",\"articleSection\":[\"Aptamers\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/\",\"name\":\"Aptamers: A Novel Therapeutic Oligonucleotide\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._a_bioscientist_in_a_lab_filled_with_light_studying_apta_3aac6d2e-4067-4208-8ce6-aed99945d942.png\",\"datePublished\":\"2023-11-15T16:34:41+00:00\",\"dateModified\":\"2026-04-13T18:24:46+00:00\",\"description\":\"Explore the potential of aptamers as a novel therapeutic in medicine with high specificity and versatility for disease treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._a_bioscientist_in_a_lab_filled_with_light_studying_apta_3aac6d2e-4067-4208-8ce6-aed99945d942.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._a_bioscientist_in_a_lab_filled_with_light_studying_apta_3aac6d2e-4067-4208-8ce6-aed99945d942.png\",\"width\":1456,\"height\":816,\"caption\":\"bio scientist in a lab\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamers-a-novel-therapeutic-oligonucleotide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptamers: A Novel Therapeutic Oligonucleotide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\",\"name\":\"Gregory Penner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"caption\":\"Gregory Penner\"},\"description\":\"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apt\u00e1meros: Un Oligonucle\u00f3tido Terap\u00e9utico Innovador","description":"Explore the potential of aptamers as a novel therapeutic in medicine with high specificity and versatility for disease treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/es\/aptamers-a-novel-therapeutic-oligonucleotide\/","og_locale":"es_ES","og_type":"article","og_title":"Aptamers: A Novel Therapeutic Oligonucleotide","og_description":"Explore the potential of aptamers as a novel therapeutic in medicine with high specificity and versatility for disease treatment.","og_url":"https:\/\/neoaptamers.com\/es\/aptamers-a-novel-therapeutic-oligonucleotide\/","og_site_name":"neoaptamers","article_published_time":"2023-11-15T16:34:41+00:00","article_modified_time":"2026-04-13T18:24:46+00:00","og_image":[{"width":1456,"height":816,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._a_bioscientist_in_a_lab_filled_with_light_studying_apta_3aac6d2e-4067-4208-8ce6-aed99945d942.png","type":"image\/png"}],"author":"Gregory Penner","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Gregory Penner","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/#article","isPartOf":{"@id":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/"},"author":{"name":"Gregory Penner","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad"},"headline":"Aptamers: A Novel Therapeutic Oligonucleotide","datePublished":"2023-11-15T16:34:41+00:00","dateModified":"2026-04-13T18:24:46+00:00","mainEntityOfPage":{"@id":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/"},"wordCount":555,"publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"image":{"@id":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._a_bioscientist_in_a_lab_filled_with_light_studying_apta_3aac6d2e-4067-4208-8ce6-aed99945d942.png","articleSection":["Aptamers"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/","url":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/","name":"Apt\u00e1meros: Un Oligonucle\u00f3tido Terap\u00e9utico Innovador","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/#primaryimage"},"image":{"@id":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._a_bioscientist_in_a_lab_filled_with_light_studying_apta_3aac6d2e-4067-4208-8ce6-aed99945d942.png","datePublished":"2023-11-15T16:34:41+00:00","dateModified":"2026-04-13T18:24:46+00:00","description":"Explore the potential of aptamers as a novel therapeutic in medicine with high specificity and versatility for disease treatment.","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/#primaryimage","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._a_bioscientist_in_a_lab_filled_with_light_studying_apta_3aac6d2e-4067-4208-8ce6-aed99945d942.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._a_bioscientist_in_a_lab_filled_with_light_studying_apta_3aac6d2e-4067-4208-8ce6-aed99945d942.png","width":1456,"height":816,"caption":"bio scientist in a lab"},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/aptamers-a-novel-therapeutic-oligonucleotide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"Aptamers: A Novel Therapeutic Oligonucleotide"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]},{"@type":"Person","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad","name":"Gregory Penner","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","caption":"Gregory Penner"},"description":"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team."}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/5613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/comments?post=5613"}],"version-history":[{"count":1,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/5613\/revisions"}],"predecessor-version":[{"id":5614,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/5613\/revisions\/5614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/media\/5615"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/media?parent=5613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/categories?post=5613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/tags?post=5613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}